Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea.
Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S77-88. doi: 10.4111/icu.2016.57.S1.S77. Epub 2016 May 25.
Urothelial carcinomas of the urinary bladder have diverse biological and functional characteristics, and numerous factors are likely to be involved in recurrence, progression, and patient survival. While several molecular markers used to evaluate the development and prognosis of bladder cancer have been studied, they are of limited value; therefore, new molecular parameters useful for predicting the prognosis of bladder cancer patients (particularly patients at high risk of progression and recurrence) are required. Recent progress in the understanding of epigenetic modification and gene silencing has provided new opportunities for the detection, treatment, and prevention of cancer. Methylation is an important molecular mechanism in bladder cancer and may have utility as a prognostic and/or diagnostic marker. This review discusses the epigenetic issues involved in the detection and prediction of bladder cancer.
膀胱尿路上皮癌具有多种生物学和功能特征，许多因素可能参与复发、进展和患者生存。虽然已经研究了几种用于评估膀胱癌发展和预后的分子标志物，但它们的价值有限；因此，需要新的分子参数来预测膀胱癌患者（尤其是有进展和复发高风险的患者）的预后。近年来，对表观遗传修饰和基因沉默的认识取得了进展，为癌症的检测、治疗和预防提供了新的机会。甲基化是膀胱癌中的一个重要分子机制，可能作为一种预后和/或诊断标志物具有实用性。本文综述了膀胱癌检测和预测中涉及的表观遗传问题。
